Gln --> Arg 191 polymorphism of paraoxonase and Parkinson's disease.
We investigated the Gln --> Arg 191 polymorphism in paraoxonase (PON1) in St. Petersburg population, in three clinically differentiated groups of patients with Parkinson's disease (PD) and in the symptomatic tremor group. A new approach for Gln --> Arg 191 PON1 polymorphism genotyping is suggested. No significant differences in the groups studies as compared to the controls was observed.
Akhmedova
S
S
Laboratory of Human Molecular Genetics, St. Petersburg Nuclear Physics Institute, Russian Academy of Science, Russia.
Anisimov
S
S
Yakimovsky
A
A
Schwartz
E
E
D000368:Aged; D000483:Alleles; D019943:Amino Acid Substitution; D001120:Arginine / Q000235:genetics*; D043303:Aryldialkylphosphatase; D001483:Base Sequence; D004247:DNA / Q000235:genetics / Q000378:metabolism; D004262:DNA Restriction Enzymes / Q000378:metabolism; D015253:Deoxyribonucleases, Type I Site-Specific; D004950:Esterases / Q000235:genetics*; D005787:Gene Frequency; D005838:Genotype; D005973:Glutamine / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000201:enzymology / Q000235:genetics*; D011110:Polymorphism, Genetic
D005973:Glutamine; D004247:DNA; D001120:Arginine; D004950:Esterases; D004262:DNA Restriction Enzymes; D015253:Deoxyribonucleases, Type I Site-Specific; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human